4.5 Article

Treatment of primary aldosteronism

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2010.10.001

关键词

primary aldosteronism; mineralocorticoid receptor; adrenalectomy; spironolactone; eplerenone; conn's adenoma

资金

  1. National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish

向作者/读者索取更多资源

The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25 mg/day spironolactone with titration up to 100 mg/day, alternatively 50-100 mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. (C) 2010 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据